Aurora Cannabis (ACB) and others Receive Price Upgrades Following CBD Trial Update & Research Results

June 11, 2019

Canadian marijuana giant Aurora Cannabis (ACB) will be announcing fiscal Q3 2019 earnings this week, and some analysts are upgrading their buy status (QT5’s) going into the second quarter. While the trading as of late has been less than stellar, some of the top analysts are significantly raising estimates right before earnings and suggesting the Canadian marijuana giant might surge in the second quart of 2019 due to a number of new research that has been released. Furthermore, GMP’s Martin Landry maintains a Buy rating on Aurora stock with a price target of C$15 — or US$11.13 —  positioning the company for an estimated 40% gain over today’s closing price.

Nico S. Wolff of SRF Financial

….on the other hand, you have companies like Aurora Cannabis who will almost certainly be constructing major acquisitions and deals to stay relevant in the industry following the collosal deal made by Canopy growth recently. High stress for the company, but highly beneficial for shareholders.

The first public FDA trials have been in progress for much of April, with the first verdict to be released to the public in the month of May, with regulation of CBD additives in foods being the main point of discussion. Top Cannabis companies such as Aphria (NYSE:APHA), Cronos Group (NASDAQ:CRON), Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) are among the most anticipated cannabis stocks to monitor during these trials, which is set to take place in April to look into how the FDA might legalize CBD-additives in food products. These four cannabis giants stand to benefit significantly from a positive out-come of the trails, which ultimately aim to loosen the constraints of adding cannabis related products to food and drinks.

Nachshol Cohen, Founder of Cannabium, the first CBD marketplace, said:

“According to the astonishing report, eighty percent of the children reported improved functioning! We hope that this research will help to bring about a conceptual change by regulators and policymakers, which will lead to a scientific momentum that will unequivocally demonstrate the positive effects of cannabis on a variety of health problems.”


Leave a Reply

Your email address will not be published. Required fields are marked *